Key Takeaways NVO dominates the GLP-1 drugs market with Ozempic, Rybelsus and Wegovy driving diabetes and obesity sales.NVO secured FDA approval for oral Wegovy, the first GLP-1 pill, with strong early U.S. demand reported.VKTX's oral VK2735 showed mixed phase II data, while phase III SC studies are ongoing with data due in 2027.Novo Nordisk (NVO) and Viking Therapeutics (VKTX) have emerged as notable players in the obesity space.A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs ...